You are here

NOVEL BASE BORONATED OLIGONUCLEOTIDES FOR BORON NEUTRON CAPTURE THERAPY

Award Information
Agency: Department of Energy
Branch: N/A
Contract: N/A
Agency Tracking Number: 10814
Amount: $499,885.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1990
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2811 O'berry St
Raleigh, NC 27607
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Dr Bernard F Spielvogel
 Principal Investigator
 (919) 832-2044
Business Contact
Phone: () -
Research Institution
N/A
Abstract

BORON NEUTRON CAPTURE THERAPY (BNCT) HAS A CLEAR THEORETICALADVANTAGE OVER OTHER TECHNIQUES AS A METHOD OF DELIVERING CELL KILLING RADIATION TO TUMORS. NEW BORON COMPOUNDS ARE NEEDED THAT CAN SELECTIVELY LOCALIZE IN TUMORS AND, UPON CAPTURE OF THERMAL OR EPITHERMAL NEUTRONS, PRODUCE RADIATIONTO KILL TUMOR CELLS BUT SPARE NORMAL TISSUE AND BLOOD. BNCTEFFECTIVENESS WOULD BE GREATEST IF THE BORON TARGETED THE CELL NUCLEUS AND LOWER CONCENTRATIONS COULD BE USED. PHASE I WILL SYNTHESIZE BORONATED OLIGONUCLEOTIDES THAT ARE RESISTANT TO NUCLEASES AND THAT SHOULD READILY ENTER CELLS AND TARGET (BY AN "ANTISENSE" MECHANISM) THE DNA OR RNA NUCLEAR MATERIAL OF TUMOR CELLS. THE OLIGONUCLEOTIDES WILL BE PREPARED BOTH CHEMICALLY AND ENZYMATICALLY USING NUCLEOSIDES THAT HAVE BEEN BORONATED ON BASE POSITIONS, AFFECTING BASE PAIRING ABILITIES AND OTHER NORMAL ACTIVITY ONLY MINIMALLY (IF AT ALL). OF CONSIDERABLE ADDED VALUE IS THE EXPECTED ANTI-TUMOR ACTIVITY OF THE BORONATED OLIGONUCLEOTIDES IN ADDITION TO THAT PROVIDED BY BNCT.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government